Novo Nordisk's reply to call for withdrawal of liraglutide.
Alan
A
Moses
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D056737:Safety-Based Drug Withdrawals
D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1